Literature DB >> 30216085

Prognosticating Outcomes in Interstitial Lung Disease by Mediastinal Lymph Node Assessment. An Observational Cohort Study with Independent Validation.

Ayodeji Adegunsoye1, Justin M Oldham2, Catherine Bonham1, Cara Hrusch1, Paul Nolan3, Wesley Klejch3, Shashi Bellam4, Uday Mehta5, Kiran Thakrar5, Janelle Vu Pugashetti2, Aliya N Husain6, Steven M Montner3, Christopher M Straus3, Rekha Vij1, Anne I Sperling1,7, Imre Noth8, Mary E Strek1, Jonathan H Chung3.   

Abstract

RATIONALE: Mediastinal lymph node (MLN) enlargement on chest computed tomography (CT) is prevalent in patients with interstitial lung disease (ILD) and may reflect immunologic activation and subsequent cytokine-mediated immune cell trafficking.
OBJECTIVES: We aimed to determine whether MLN enlargement on chest CT predicts clinical outcomes and circulating cytokine levels in ILD.
METHODS: MLN measurements were obtained from chest CT scans of patients with ILD at baseline evaluation over a 10-year period. Patients with sarcoidosis and drug toxicity-related ILD were excluded. MLN diameter and location were assessed. Plasma cytokine levels were analyzed in a subset of patients. The primary outcome was transplant-free survival (TFS). Secondary outcomes included all-cause and respiratory hospitalizations, lung function, and plasma cytokine concentrations. Cox regression was used to assess mortality risk. Outcomes were assessed in three independent ILD cohorts.
MEASUREMENTS AND MAIN RESULTS: Chest CT scans were assessed in 1,094 patients (mean age, 64 yr; 52% male). MLN enlargement (≥10 mm) was present in 66% (n = 726) and strongly predicted TFS (hazard ratio [HR], 1.53; 95% confidence interval [CI], 1.12-2.10; P = 0.008) and risk of all-cause and respiratory hospitalizations (internal rate of return [IRR], 1.52; 95% CI, 1.17-1.98; P = 0.002; and IRR, 1.71; 95% CI, 1.15-2.53; P = 0.008, respectively) when compared with subjects with MLN <10 mm. Patients with MLN enlargement had lower lung function and decreased plasma concentrations of soluble CD40L (376 pg/ml vs. 505 pg/ml, P = 0.001) compared with those without MLN enlargement. Plasma IL-10 concentration >45 pg/ml predicted mortality (HR, 4.21; 95% CI, 1.21-14.68; P = 0.024). Independent analysis of external datasets confirmed these findings.
CONCLUSIONS: MLN enlargement predicts TFS and hospitalization risk in ILD and is associated with decreased levels of a key circulating cytokine, soluble CD40L. Incorporating MLN and cytokine findings into current prediction models might improve ILD prognostication.

Entities:  

Keywords:  interstitial lung disease; mediastinal lymph nodes; mortality; pulmonary fibrosis

Mesh:

Year:  2019        PMID: 30216085      PMCID: PMC6423102          DOI: 10.1164/rccm.201804-0761OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  64 in total

1.  Ectopic respiratory epithelial cell differentiation in bronchiolised distal airspaces in idiopathic pulmonary fibrosis.

Authors:  Laurent Plantier; Bruno Crestani; Susan E Wert; Monique Dehoux; Barbara Zweytick; Andreas Guenther; Jeffrey A Whitsett
Journal:  Thorax       Date:  2011-03-21       Impact factor: 9.139

Review 2.  Pulmonary tuberculosis: up-to-date imaging and management.

Authors:  Yeon Joo Jeong; Kyung Soo Lee
Journal:  AJR Am J Roentgenol       Date:  2008-09       Impact factor: 3.959

3.  Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis.

Authors:  Yong Huang; Shwu-Fan Ma; Milena S Espindola; Rekha Vij; Justin M Oldham; Gary B Huffnagle; John R Erb-Downward; Kevin R Flaherty; Beth B Moore; Eric S White; Tong Zhou; Jianrong Li; Yves A Lussier; MeiLan K Han; Naftali Kaminski; Joe G N Garcia; Cory M Hogaboam; Fernando J Martinez; Imre Noth
Journal:  Am J Respir Crit Care Med       Date:  2017-07-15       Impact factor: 21.405

4.  Prognostic factors in pathological stage IB nonsmall cell lung cancer greater than 3 cm.

Authors:  J-J Hung; W-J Jeng; W-H Hsu; S-F Lin; C-C Hsieh; B-S Huang; M-H Huang; J-S Liu; T-Y Chou; Y-C I Wu
Journal:  Eur Respir J       Date:  2010-06-01       Impact factor: 16.671

5.  African-American race and mortality in interstitial lung disease: a multicentre propensity-matched analysis.

Authors:  Ayodeji Adegunsoye; Justin M Oldham; Shashi K Bellam; Jonathan H Chung; Paul A Chung; Kathleen M Biblowitz; Steven Montner; Cathryn Lee; Scully Hsu; Aliya N Husain; Rekha Vij; Gokhan Mutlu; Imre Noth; Matthew M Churpek; Mary E Strek
Journal:  Eur Respir J       Date:  2018-06-14       Impact factor: 16.671

6.  Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.

Authors:  Talmadge E King; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Phil Hormel; Lisa Lancaster; Paul W Noble; Steven A Sahn; Javier Szwarcberg; Michiel Thomeer; Dominique Valeyre; Roland M du Bois
Journal:  Lancet       Date:  2009-06-29       Impact factor: 79.321

Review 7.  Immune Mechanisms in Pulmonary Fibrosis.

Authors:  Saeed Kolahian; Isis E Fernandez; Oliver Eickelberg; Dominik Hartl
Journal:  Am J Respir Cell Mol Biol       Date:  2016-09       Impact factor: 6.914

8.  Heterogeneity in Unclassifiable Interstitial Lung Disease. A Systematic Review and Meta-Analysis.

Authors:  Sabina A Guler; Kina Ellison; Mohmmed Algamdi; Harold R Collard; Christopher J Ryerson
Journal:  Ann Am Thorac Soc       Date:  2018-07

9.  Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis.

Authors:  Stephanie Shin; Christopher S King; Nitin Puri; Oksana A Shlobin; A Whitney Brown; Shahzad Ahmad; Nargues A Weir; Steven D Nathan
Journal:  Eur Respir J       Date:  2016-02-04       Impact factor: 16.671

10.  Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death.

Authors:  Kim L Brunekreeft; Corinna Strohm; Marloes J Gooden; Anna A Rybczynska; Hans W Nijman; Götz U Grigoleit; Wijnand Helfrich; Edwin Bremer; Daniela Siegmund; Harald Wajant; Marco de Bruyn
Journal:  Mol Cancer       Date:  2014-04-17       Impact factor: 27.401

View more
  9 in total

Review 1.  Update in Interstitial Lung Disease 2019.

Authors:  Sydney B Montesi; Jolene H Fisher; Fernando J Martinez; Moisés Selman; Annie Pardo; Kerri A Johannson
Journal:  Am J Respir Crit Care Med       Date:  2020-08-15       Impact factor: 21.405

2.  CPAP Adherence, Mortality, and Progression-Free Survival in Interstitial Lung Disease and OSA.

Authors:  Ayodeji Adegunsoye; Julie M Neborak; Daisy Zhu; Benjamin Cantrill; Nicole Garcia; Justin M Oldham; Imre Noth; Rekha Vij; Tomasz J Kuzniar; Shashi K Bellam; Mary E Strek; Babak Mokhlesi
Journal:  Chest       Date:  2020-05-22       Impact factor: 9.410

3.  Thoracic lymphadenopathy as possible predictor of the onset of interstitial lung disease in systemic sclerosis patients without lung involvement at baseline visit: A retrospective analysis.

Authors:  Cinzia Rotondo; Livio Urso; Emanuela Praino; Fabio Cacciapaglia; Addolorata Corrado; Francesco Paolo Cantatore; Florenzo Iannone
Journal:  J Scleroderma Relat Disord       Date:  2020-06-02

4.  Will Adding Fibrotic Score to the GAP Score Help Predict Patient Survival?

Authors:  Jonathan H Chung
Journal:  Radiol Cardiothorac Imaging       Date:  2019-06-27

5.  Computed Tomography Honeycombing Identifies a Progressive Fibrotic Phenotype with Increased Mortality across Diverse Interstitial Lung Diseases.

Authors:  Ayodeji Adegunsoye; Justin M Oldham; Shashi K Bellam; Steven Montner; Matthew M Churpek; Imre Noth; Rekha Vij; Mary E Strek; Jonathan H Chung
Journal:  Ann Am Thorac Soc       Date:  2019-05

6.  High-titer rheumatoid factor seropositivity predicts mediastinal lymphadenopathy and mortality in rheumatoid arthritis-related interstitial lung disease.

Authors:  Albina Tyker; Iazsmin Bauer Ventura; Cathryn T Lee; Rachel Strykowski; Nicole Garcia; Robert Guzy; Renea Jablonski; Rekha Vij; Mary E Strek; Jonathan H Chung; Ayodeji Adegunsoye
Journal:  Sci Rep       Date:  2021-11-24       Impact factor: 4.379

7.  Dose-response relationship of pulmonary disorders by inhalation exposure to cross-linked water-soluble acrylic acid polymers in F344 rats.

Authors:  Tomoki Takeda; Shotaro Yamano; Yuko Goto; Shigeyuki Hirai; Yusuke Furukawa; Yoshinori Kikuchi; Kyohei Misumi; Masaaki Suzuki; Kenji Takanobu; Hideki Senoh; Misae Saito; Hitomi Kondo; George Daghlian; Young-Kwon Hong; Yasuhiro Yoshimatsu; Masanori Hirashima; Yoichiro Kobashi; Kenzo Okamoto; Takumi Kishimoto; Yumi Umeda
Journal:  Part Fibre Toxicol       Date:  2022-04-08       Impact factor: 9.112

8.  Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer Cells.

Authors:  Yong Huang; Justin M Oldham; Shwu-Fan Ma; Avraham Unterman; Shu-Yi Liao; Andrew J Barros; Catherine A Bonham; John S Kim; Rekha Vij; Ayodeji Adegunsoye; Mary E Strek; Philip L Molyneaux; Toby M Maher; Jose D Herazo-Maya; Naftali Kaminski; Bethany B Moore; Fernando J Martinez; Imre Noth
Journal:  Am J Respir Crit Care Med       Date:  2021-07-15       Impact factor: 30.528

9.  Mediastinal Lymphadenopathy in Interstitial Lung Disease. Time to Be Counted.

Authors:  Simon L F Walsh
Journal:  Am J Respir Crit Care Med       Date:  2019-03-15       Impact factor: 21.405

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.